32
Participants
Start Date
November 30, 2009
Primary Completion Date
May 31, 2013
Study Completion Date
May 31, 2013
ABT-263
ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
FCR
Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
BR
Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
Site Reference ID/Investigator# 39613, Philadelphia
Site Reference ID/Investigator# 21621, Columbus
Site Reference ID/Investigator# 17841, La Jolla
Site Reference ID/Investigator# 25899, Stanford
Site Reference ID/Investigator# 21622, Baltimore
Site Reference ID/Investigator# 17943, Houston
Collaborators (1)
Genentech, Inc.
INDUSTRY
AbbVie (prior sponsor, Abbott)
INDUSTRY